Select Clinical Trial
Protocol Number: NRG-GY005/ Ovarian/ Fallopian Tube/ Peritoneal
Protocol Title: Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Eligibility: Patient population 18 Years and older with confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer that has returned after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory).
Contact Information: (910) 715-2200